Mga Batayang Estadistika
| CIK | 1042418 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Inhibitor Therapeutics, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-13467 Inhibitor Ther |
|
| May 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-13467 Inhibitor The |
|
| March 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-13467 Inhibitor Therapeutics, Inc. |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-13467 Inhibitor |
|
| August 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-13467 Inhibitor Ther |
|
| May 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-13467 Inhibitor The |
|
| March 29, 2024 |
Exhibit 10.6 JHU EXCLUSIVE LICENSE AGREEMENT CONFIDENTIAL Confidential Treatment Requested by Inhibitor Therapeutics, Inc., IRS Employer Identification No. 30-0793665 ***CONFIDENTIAL TREATMENT REQUESTED*** NOTE: CONFIDENTIAL TREATMENT REQUESTED WITH RESPECT TO CERTAIN PORTIONS HEREOF DENOTED WITH “[***]” EXCLUSIVE LICENSE AGREEMENT Johns Hopkins University and Inhibitor Therapeutics JHU Agreement |
|
| March 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-13467 Inhibitor Therapeutics, Inc. |
|
| December 14, 2023 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2023 (December 12, 2023) Inhibitor Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-13467 30-0793665 (State or other jurisdi |
|
| December 14, 2023 |
Exhibit 99.1 Inhibitor Therapeutics, Inc. Exclusive License with Johns Hopkins University A critical milestone completed on the mission path of commercializing Itraconazole in numerous oncology indications. Inhibitor Therapeutics, Inc. (“Inhibitor”) (OTCQB:INTI) has entered into an exclusive, worldwide licensing agreement (the “License”) with Johns Hopkins University (JHU) for their U.S Patent 8,9 |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-13467 Inhibitor |
|
| October 18, 2023 |
Exhibit 3.1 INHIBITOR THERAPUTICS, INC. SCIENTIFIC ADVISORY BOARD CHARTER Adopted October 13, 2023 I. GENERAL FUNCTION The function of the Scientific Advisory Board (the “Scientific Advisory Board”) shall be to advise and make non-binding recommendations to the Board of Directors and senior management of Inhibitor Therapeutics, Inc., (the “Company”) with respect to matters relating to the business |
|
| October 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 13, 2023 Inhibitor Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-13467 30-0793665 (State or other jurisdiction of incorporatio |
|
| October 18, 2023 |
Consulting Agreement by and among Inhibitor Therapeutics, Inc., and Dr. Elizabeth Billingsley Exhibit 10.1 CONSULTING AGREEMENT THIS CONSULTING AGREEMENT (the “Agreement”) is made and entered into as of this 20th day of July, 2023, by and between Dermapharm Consulting LLC (hereinafter referred to as “Consultant”), with an address at 157 Hamilton Road, Lancaster, PA 17603, and Inhibitor Therapeutics, Inc. (the “Company”) a Delaware corporation with offices at 4905 South Westshore Blvd., Tam |
|
| August 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 29, 2023 (August 23, 2023) Inhibitor Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-13467 30-0793665 (State or other jurisdictio |
|
| August 29, 2023 |
EX-3.1 Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF INHIBITOR THERAPUTICS, INC. (a Delaware Corporation) (Adopted Effective as of July 12, 2023) These Amended and Restated Bylaws of Inhibitor Therapeutics, Inc., a Delaware corporation (the “Corporation”), are adopted pursuant to Article 12 of the Corporation’s existing Bylaws (the “Original Bylaws”) and are intended to amend, restate and replace, in |
|
| August 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-13467 Inhibitor Ther |
|
| May 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 31, 2023 (May 24, 2023) Inhibitor Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-13467 30-0793665 (State or other jurisdiction of i |
|
| May 23, 2023 |
INTI / Inhibitor Therapeutics Inc / Black Robe Capital LLC - SC 13D Activist Investment SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 INHIBITOR THERAPUTICS, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 45720M 10 5 (CUSIP Number) James McNulty c/o Inhibitor Therapeutics, Inc. 900 West Platt St., Suite 200 Tampa, Florida 33606 (Name, Address and Tele |
|
| May 23, 2023 |
INTI / Inhibitor Therapeutics Inc / TPB 2012 LLC - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Inhibitor Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 45720M 10 5 (CUSIP Number) May 5, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule purs |
|
| May 23, 2023 |
EX-99.1 EXHIBIT 99.1 JOINT FILING AGREEMENT Each of the undersigned agrees that (i) the statement on Schedule 13D relating to Black Robe Capital LLC and James McNulty, has been adopted and filed on behalf of each of them, (ii) all future amendments to such statement on Schedule 13D will, unless written notice to the contrary is delivered as described below, be jointly filed on behalf of each of th |
|
| May 23, 2023 |
EX-99.1 EXHIBIT 99.1 JOINT FILING AGREEMENT Each of the undersigned agrees that (i) the statement on Schedule 13G relating to the shares of Common Stock of TPB 2012, LLC and James Donovan, has been adopted and filed on behalf of each of them, (ii) all future amendments to such statement on Schedule 13G will, unless written notice to the contrary is delivered as described below, be jointly filed on |
|
| May 18, 2023 |
INTI / Inhibitor Therapeutics Inc / Ronald E Osman Irrevocable Trust III - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Inhibitor Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 45720M 10 5 (CUSIP Number) May 5, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule purs |
|
| May 18, 2023 |
EX-99.1 EXHIBIT 99.1 JOINT FILING AGREEMENT Each of the undersigned agrees that (i) the statement on Schedule 13G relating to the Ronald E Osman Trust III and Ronald E. Osman, has been adopted and filed on behalf of each of them, (ii) all future amendments to such statement on Schedule 13G will, unless written notice to the contrary is delivered as described below, be jointly filed on behalf of ea |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-13467 Inhibitor The |
|
| March 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-13467 Inhibitor Therapeutics, Inc. |
|
| December 19, 2022 |
Exhibit 10.1 IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE HEDGEPATH, LLC, Plaintiff, v. C.A. No. 2019-0529-JTL BRENDAN MAGRAB, STEFAN J. CROSS, DR. R. DANA ONO, ROBERT D. MARTIN, W. MARK WATSON, NICHOLAS J. VIRCA and MAYNE PHARMA VENTURES PTY LTD., Defendants, and HEDGEPATH PHARMACEUTICALS, INC., a Delaware corporation, Nominal Defendant. SAMUEL SEARS, Individually And On Behalf of All Others |
|
| December 19, 2022 |
Exhibit 10.3 INHIBITOR THERAPEUTICS, INC. EMPLOYMENT AGREEMENT This Employment Agreement (the ?Agreement?), entered into as of December 13, 2022 (the ?Effective Date?), is made by and between Inhibitor Therapeutics, Inc., a Delaware corporation (the ?Company?) and Francis E. O?Donnell (?Executive? and, together with the Company, the ?Parties?). WHEREAS, the Company desires to assure itself of the |
|
| December 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 19, 2022 ( December 13, 2022 ) Inhibitor Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-13467 30-0793665 (State or other juris |
|
| December 19, 2022 |
Exhibit 10.2 Licence Agreement Date Parties Name Mayne Pharma Ventures Pty Ltd, an Australian company ACN 168 896 357 Short form name Mayne Pharma Notice details 1538 Main North Road, Salisbury South, SA 5106 Australia Facsimile: +61 3 9614 7022 Attention: General Counsel Name Inhibitor Therapeutics, Inc., formerly known as Hedgepath Pharmaceuticals, Inc., a company incorporated in Delaware, succe |
|
| December 19, 2022 |
Exhibit 10.4 INHIBITOR THERAPEUTICS, INC. EMPLOYMENT AGREEMENT This Employment Agreement (the ?Agreement?), entered into as of December 13, 2022 (the ?Effective Date?), is made by and between Inhibitor Therapeutics, Inc., a Delaware corporation (the ?Company?) and James A. McNulty (?Executive? and, together with the Company, the ?Parties?). WHEREAS, the Company desires to assure itself of the serv |
|
| November 14, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0 |
|
| September 15, 2022 |
Exhibit 99.1 IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE HEDGEPATH, LLC, Plaintiff, v. C.A. No. 2019-0529-JTL BRENDAN MAGRAB, STEFAN J. CROSS, DR. R. DANA ONO, ROBERT D. MARTIN, W. MARK WATSON, NICHOLAS J. VIRCA and MAYNE PHARMA VENTURES PTY LTD., Defendants, and HEDGEPATH PHARMACEUTICALS, INC., a Delaware corporation, Nominal Defendant. SAMUEL SEARS, Individually And On Behalf of All Others |
|
| September 15, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 15, 2022 (September 9, 2022) Inhibitor Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-13467 30-0793665 (State or other jurisd |
|
| August 12, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-13 |
|
| June 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2022 (June 1, 2022) Inhibitor Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-13467 30-0793665 (State or other jurisdiction of i |
|
| May 13, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-1 |
|
| March 30, 2022 |
Exhibit 10.13 1 March 2022 Mark Watson Inhibitor Therapeutics [email protected] Dear Mark Second Loan Amendment Mayne Pharma Ventures Pty Ltd (Mayne Pharma) is offering to amend the loan outlined in our letter signed 12 December 2020, as amended on 10 January 2022 (Loan) to provide a loan to Inhibitor Therapeutics, Inc. (INTI), as set out below. Line Amount: The Facility Limit is increased by |
|
| March 30, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-13467 Inhibitor T |
|
| January 18, 2022 |
Exhibit 10.1 10 January 2022 Mark Watson Inhibitor Therapeutics Dear Mark Loan Amendment Mayne Pharma Ventures Pty Ltd (Mayne Pharma) is offering to amend the loan outlined in our letter signed 12 December 2020 (Loan) to provide a loan to Inhibitor Therapeutics, Inc. (INTI), as set out below. Line Amount: The Facility Limit is increased by USD50,000 to USD281,000. Availability: The USD50,000 incre |
|
| January 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 18, 2022 (January 13, 2022) Inhibitor Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-13467 30-0793665 (State or other jurisdict |
|
| November 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-13467 Inhibitor |
|
| August 13, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-13 |
|
| May 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-1 |
|
| March 26, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-13467 Inhibitor T |
|
| January 6, 2021 |
8-K 1 d64046d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 6, 2021 (December 31, 2020) Inhibitor Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-13467 30-0793665 ( |
|
| December 17, 2020 |
EX-10.1 Exhibit 10.1 12 December 2020 Mark Watson, Dana Ono and Debra Peattie Inhibitor Therapeutics, Inc. Special Committee [email protected] Dear INTI Special Committee Loan offer Mayne Pharma Ventures Pty Ltd (Mayne Pharma) offers a loan to Inhibitor Therapeutics, Inc. (INTI) from 14 December 2020 in USD up to the Facility Limit for Purpose (both as defined below) as set out in this letter. |
|
| December 17, 2020 |
8-K 1 d64746d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 17, 2020 (December 12, 2020) Inhibitor Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-13467 30-0793665 |
|
| November 16, 2020 |
10-Q 1 d24961d10q.htm FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period |
|
| September 23, 2020 |
8-K 1 d33676d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 23, 2020 (September 17, 2020) Inhibitor Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-13467 30-07936 |
|
| August 12, 2020 |
10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| June 30, 2020 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2020 (June 28, 2020) Inhibitor Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-13467 30-0793665 (State or other jurisdictio |
|
| June 8, 2020 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2020 (June 4, 2020) Inhibitor Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-13467 30-0793665 (State or other jurisdiction |
|
| May 6, 2020 |
Promissory Note, dated May 2, 2020, by and between the Company and Citibank, N.A. EX-10.1 Exhibit 10.1 DocuSign Envelope ID: E25578FB-4593-FFC1-9237-059352B386FA U.S. Small Business Administration PAYCHECK PROTECTION PROGRAM LOAN NOTE SBA Loan# PLP# 37765472-00 SBA Loan Name INHIBITOR THERAPEUTICS, INC. Date 05/02/2020 Loan Amount $41,600.00 Interest Rate 1.00% Borrower INHIBITOR THERAPEUTICS, INC. Lender Citibank, N.A. Maturity Date 5/2/2022 1. PROMISE TO PAY: In return for th |
|
| May 6, 2020 |
8-K 1 d187824d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2020 (May 3, 2020) Inhibitor Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-13467 30-0793665 (State or |
|
| May 1, 2020 |
10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 16, 2020 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 16, 2020 (April 10, 2020) Inhibitor Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-13467 30-0793665 (State or other jurisdict |
|
| March 30, 2020 |
INTI / Inhibitor Therapeutics, Inc. 10-K - Annual Report - 10-K 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| January 3, 2020 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 31, 2019 Inhibitor Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-13467 30-0793665 (State or other jurisdiction of incorpo |
|
| December 5, 2019 |
INTI / Inhibitor Therapeutics, Inc. DEF 14C - - DEF 14C DEF 14C 1 d809223ddef14c.htm DEF 14C SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 INFORMATION STATEMENT PURSUANT TO SECTION 14(C) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED SCHEDULE 14C (RULE 14C-101) Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ☐ Preliminary Information Statement ☐ Confidential, for Use of t |
|
| November 7, 2019 |
EX-10.1 Exhibit 10.1 Redactions with respect to certain portions hereof denoted with “***” Execution Date: August 27, 2019 Effective Date: August 20, 2019 SUBLICENSE AGREEMENT BETWEEN MAYNE PHARMA INTERNATIONAL PTY LTD & INHIBITOR THERAPEUTICS, INC. SUBLICENSE AGREEMENT THIS SUBLICENSE AGREEMENT (this “Agreement”) is executed on August 27, 2019 and entered into effective as of August 20, 2019 by a |
|
| November 7, 2019 |
INTI / Inhibitor Therapeutics, Inc. 10-Q - Quarterly Report - 10-Q 10-Q 1 d787025d10q.htm 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from |
|
| October 31, 2019 |
EX-99.1 Exhibit 99.1 INHIBITOR Therapeutics Appoints Dr. Debra Peattie to its Board of Directors Industry Veteran Brings 30 Years of Experience to Support INTI’s Biopharmaceutical and Corporate Programs Tampa, Fla. — October 31, 2019 — INHIBITOR Therapeutics, Inc. (OTCQB:INTI), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to inh |
|
| October 31, 2019 |
8-K 1 d625780d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2019 (October 30, 2019) Inhibitor Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-13467 30-0793665 |
|
| August 27, 2019 |
Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 27, 2019 (August 21, 2019) Inhibitor Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-13467 30-0793665 (State or other jurisdi |
|
| August 20, 2019 |
Certificate of Amendment to the Company’s Certificate of Incorporation, dated August 20, 2019 (14) Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE CERTIFICATE OF INCORPORATION OF HEDGEPATH PHARMACEUTICALS, INC. The undersigned, for the purposes of amending the Certificate of Incorporation of HedgePath Pharmaceuticals, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify that: FIRS |
|
| August 20, 2019 |
EX-99.2 Corporate Presentation August 2019 OTCQB:INTI Exhibit 99.2 Cautionary Note on Forward-Looking Statements and Disclaimers This presentation includes or incorporates by reference statements that constitute “forward-looking statements” within the meaning of the U.S. federal securities laws. These statements relate to future events or to our future performance, and involve significant known an |
|
| August 20, 2019 |
8-K 1 d793055d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 20, 2019 (August 19, 2019) Inhibitor Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-13467 30-0793665 (S |
|
| August 20, 2019 |
EX-99.1 Exhibit 99.1 HedgePath Pharmaceuticals Announces Name Change to INHIBITOR Therapeutics, Inc. and Ticker Symbol Change to “INTI” Effective August 20, 2019 New Corporate Brand Exemplifies Multiple Near-term Growth Opportunities Involving Lead Technology, SUBA™- Itraconazole, Inhibiting the Hedgehog Signaling Pathway INHIBITOR to Hold End of Phase 2 Meeting with FDA in Q4 2019 Prior to Filing |
|
| August 12, 2019 |
HPPI / HedgePath Pharmaceuticals, Inc. 10-Q - Quarterly Report - 10-Q 10-Q 1 d747883d10q.htm 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to C |
|
| July 17, 2019 |
Regulation FD Disclosure, Other Events 8-K 1 d767489d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 17, 2019 HedgePath Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-13467 30-0793665 (State or other jur |
|
| July 1, 2019 |
8-K 1 d774368d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2019 HedgePath Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-13467 30-0793665 (State or other jur |
|
| June 19, 2019 |
8-K 1 d756566d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2019 HedgePath Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-13467 30-0793665 (State or other jur |
|
| June 3, 2019 |
HPPI / HedgePath Pharmaceuticals, Inc. DEF 14C - - DEF 14C DEF 14C SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 INFORMATION STATEMENT PURSUANT TO SECTION 14(C) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED SCHEDULE 14C (RULE 14C-101) Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ☐ Preliminary Information Statement ☒ Definitive Information Statement ☐ Confidential, for Us |
|
| May 24, 2019 |
HPPI / HedgePath Pharmaceuticals, Inc. PRE 14C - - PRE 14C SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 INFORMATION STATEMENT PURSUANT TO SECTION 14(C) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED SCHEDULE 14C (RULE 14C-101) Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ☒ Preliminary Information Statement ☐ Definitive Information Statement ☐ Confidential, for Use of the |
|
| May 9, 2019 |
HPPI / HedgePath Pharmaceuticals, Inc. 10-Q Quarterly Report FORM 10-Q 10-Q 1 d709188d10q.htm FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fro |
|
| April 26, 2019 |
HPPI / HedgePath Pharmaceuticals, Inc. POS AM POS AM POS AM Table of Contents As filed with the Securities and Exchange Commission on April 26, 2019 Registration No. |
|
| April 15, 2019 |
Financial Statements and Exhibits, Other Events 8-K 1 d696673d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 15, 2019 HedgePath Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-13467 30-0793665 (State or other ju |
|
| April 15, 2019 |
W. Mark Watson Elected as Chairman of the Board of HedgePath Pharmaceuticals EX-99.1 Exhibit 99.1 W. Mark Watson Elected as Chairman of the Board of HedgePath Pharmaceuticals Tampa, FL, April 15, 2019 – HedgePath Pharmaceuticals, Inc. (OTCQB: HPPI), a pharmaceutical development company focused on discovering, developing and ultimately commercializing innovative therapies for patients with cancer and non-cancerous proliferation disorders, announced today that HedgePath’s Bo |
|
| March 7, 2019 |
EX-10.7 Exhibit 10.7 AGREEMENT This AGREEMENT (this “Agreement”) is entered into by and among HEDGEPATH PHARMACEUTICALS, INC., a Delaware corporation (“HPPI”), MAYNE PHARMA VENTURES PTY LTD, an Australian company ACN 168 896 357 (“Mayne Pharma”), and MAYNE PHARMA INTERNATIONAL PTY LTD, an Australian company ACN 007 870 984 (“Mayne Pharma International” and together with Mayne Pharma, collectively, |
|
| March 7, 2019 |
EX-10.5 Confidential Treatment Requested by HedgePath Pharmaceuticals, Inc., IRS Employer Identification No. 30-0793665 Exhibit 10.5 ***CONFIDENTIAL TREATMENT REQUESTED*** Note: Confidential treatment requested with respect to certain portions hereof denoted with “***” Third Amended and Restated Supply and License Agreement Mayne Pharma Ventures Pty Ltd (Mayne Pharma) HedgePath Pharmaceuticals, In |
|
| March 7, 2019 |
EX-10.6 Confidential Treatment Requested by HedgePath Pharmaceuticals, Inc., IRS Employer Identification No. 30-0793665 Exhibit 10.6 ***CONFIDENTIAL TREATMENT REQUESTED*** Note: Confidential treatment requested with respect to certain portions hereof denoted with “***” December 17, 2018 AMENDED AND RESTATED SUBLICENSE AGREEMENT BETWEEN MAYNE PHARMA INTERNATIONAL PTY LTD & HEDGEPATH PHARMACEUTICALS |
|
| March 7, 2019 |
HPPI / HedgePath Pharmaceuticals, Inc. FORM 10-K (Annual Report) 10-K 1 d668655d10k.htm FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission |
|
| February 13, 2019 |
Regulation FD Disclosure, Other Events 8-K 1 d705755d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2019 (February 11, 2019) HedgePath Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-13467 3 |
|
| January 8, 2019 |
DEF 14C SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 INFORMATION STATEMENT PURSUANT TO SECTION 14(C) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED SCHEDULE 14C (RULE 14C-101) Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ☐ Preliminary Information Statement ☐ Confidential, for Use of the Commission Only (as permit |
|
| December 31, 2018 |
8-K 1 d672710d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 31, 2018 HedgePath Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-13467 30-0793665 (State or |
|
| December 31, 2018 |
Exhibit 10.2 CONFIDENTIAL VIA EMAIL December 31 2018 Garrison J. Hasara, CPA c/o HedgePath Pharmaceuticals, Inc. 324 S. Hyde Park Avenue, Suite 350 Tampa, Florida 33606 Re: Terms of Employment Dear Garry: HedgePath Pharmaceuticals, Inc. (the “Company”) hereby extends to you an offer to continue your employment with the Company under the revised employment terms as set forth below. This letter is r |
|
| December 31, 2018 |
Employment Letter Agreement, dated December 31, 2018, between the Company and Nicholas J. Virca (12) EX-10.1 2 d672710dex101.htm EX-10.1 Exhibit 10.1 CONFIDENTIAL VIA EMAIL December 31, 2018 Mr. Nicholas J. Virca c/o HedgePath Pharmaceuticals, Inc. 324 S. Hyde Park Avenue, Suite 350 Tampa, Florida 33606 Re: Terms of Employment Dear Nick: HedgePath Pharmaceuticals, Inc. (the “Company”) hereby extends to you an offer to continue your employment with the Company under the revised employment terms as |
|
| December 28, 2018 |
HPPI / HedgePath Pharmaceuticals, Inc. PRE 14C PRE 14C 1 d679573dpre14c.htm PRE 14C SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 INFORMATION STATEMENT PURSUANT TO SECTION 14(C) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED SCHEDULE 14C (RULE 14C-101) Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ☒ Preliminary Information Statement ☐ Confidential, for Use of t |
|
| December 21, 2018 |
HPPI / HedgePath Pharmaceuticals, Inc. DEF 14C DEF 14C 1 d678464ddef14c.htm DEF 14C SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 INFORMATION STATEMENT PURSUANT TO SECTION 14(C) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED SCHEDULE 14C (RULE 14C-101) Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ☐ Preliminary Information Statement ☐ Confidential, for Use of t |
|
| December 19, 2018 |
Exhibit 99.1 JOINT FILING AGREEMENT Each of the undersigned hereby agrees that this Amendment No. 10 to Schedule 13D is being filed with the U.S. Securities and Exchange Commission on behalf of each of the undersigned pursuant to Rule 13d-1(k) under the U.S. Securities Exchange Act of 1934, as amended. Date: December 18, 2018 Mayne Pharma Ventures Pty Ltd /s/ Nick Freeman Nick Freeman, Company Sec |
|
| December 19, 2018 |
SC 13D/A 1 tv509463sc13d-a.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 10)* HedgePath Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 42278K 102 (CUSIP Number) Kate Rintoul Mayne Pharma Ventures Pty Ltd 1538 Main North Road, Salisbur |
|
| December 17, 2018 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 17, 2018 HedgePath Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-13467 30-0793665 (State or other jurisdiction of inco |
|
| December 17, 2018 |
EX-99.1 Exhibit 99.1 HedgePath Pharmaceuticals and Mayne Pharma Enter into Updated Collaboration and Funding Agreements HPPI to transfer SUBA-Itraconazole BCCNS clinical program to Mayne Pharma in consideration of up to $5 million in new funding from Mayne Pharma and a 9% royalty on future SUBA-Itraconazole BCCNS sales in the U.S. With new funding, HPPI to move towards IND filing during 2019 and r |
|
| November 14, 2018 |
HPPI / HedgePath Pharmaceuticals, Inc. 10-Q (Quarterly Report) 10-Q 1 d613945d10q.htm 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2018 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission fil |
|
| November 5, 2018 |
8-K 1 d650579d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2018 HedgePath Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-13467 30-0793665 (State or other |
|
| November 5, 2018 |
MAYNE PHARMA VENTURES PTY LTD 1528 Main north road salisbury south 5106 SA Exhibit 99.2 MAYNE PHARMA VENTURES PTY LTD 1528 Main north road salisbury south 5106 SA Australia November 2, 2018 VIA E-MAIL HedgePath Pharmaceuticals, Inc. 324 South Hyde Park Avenue, Suite 350 Tampa, Florida 33606 Attention: · Dana Ono [email protected] · Bob Martin [email protected] · Mark Watson [email protected] Copy to: · Lawrence A. Rosenbloom, Ellenoff Grossman & Schole LLP, lr |
|
| November 5, 2018 |
EX-99.1 2 tv506195ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 JOINT FILING AGREEMENT Each of the undersigned hereby agrees that this Amendment No. 9 to Schedule 13D is being filed with the U.S. Securities and Exchange Commission on behalf of each of the undersigned pursuant to Rule 13d-1(k) under the U.S. Securities Exchange Act of 1934, as amended. Date: November 5, 2018 Mayne Pharma Ventures Pty Ltd /s |
|
| November 5, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 9)* HedgePath Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 42278K 102 (CUSIP Number) Kate Rintoul Mayne Pharma Ventures Pty Ltd 1538 Main North Road, Salisbury South 5106 SA, Australia 61 3 8614 7711 |
|
| July 23, 2018 |
HPPI / HedgePath Pharmaceuticals, Inc. FORM 10-Q (Quarterly Report) 10-Q 1 d557556d10q.htm FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2018 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from |
|
| July 10, 2018 |
EX-99.1 Exhibit 99.1 HedgePath Pharmaceuticals Closes Second Tranche of Mayne Pharma Financing Additional $1.6 million in preferred stock and warrant funding to support SUBA BCCNS regulatory program HPPI to meet with FDA this month to discuss proposed 2018 NDA filing TAMPA, Fla., July 9, 2018 /PRNewswire/ — HedgePath Pharmaceuticals, Inc. (OTCQB:HPPI), a clinical stage biopharmaceutical company th |
|
| July 10, 2018 |
Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 10, 2018 (July 6, 2018) HedgePath Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-13467 30-0793665 (State or other jurisdict |
|
| July 6, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 8)* HedgePath Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 42278K 102 (CUSIP Number) Kate Rintoul Mayne Pharma Ventures Pty Ltd 1538 Main North Road, Salisbury South 5106 SA, Australia 61 3 8614 7711 |
|
| July 6, 2018 |
Exhibit 99.1 JOINT FILING AGREEMENT Each of the undersigned hereby agrees that this Amendment No. 8 to Schedule 13D is being filed with the U.S. Securities and Exchange Commission on behalf of each of the undersigned pursuant to Rule 13d-1(k) under the U.S. Securities Exchange Act of 1934, as amended. Date: July 6, 2018 Mayne Pharma Ventures Pty Ltd /s/ Nick Freeman Nick Freeman, Company Secretary |
|
| May 1, 2018 |
HPPI / HedgePath Pharmaceuticals, Inc. 10-Q (Quarterly Report) 10-Q 1 d558032d10q.htm 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2018 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to |
|
| April 4, 2018 |
HPPI / HedgePath Pharmaceuticals, Inc. POS AM POS AM Table of Contents As filed with the Securities and Exchange Commission on April 4, 2018 Registration No. |
|
| February 16, 2018 |
HPPI / HedgePath Pharmaceuticals, Inc. FORM 10-K (Annual Report) Form 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| January 11, 2018 |
Certificate of Designation of Series B Preferred Stock of the Company, dated January 8, 2018 (13) EX-3.1 2 d523601dex31.htm EX-3.1 Exhibit 3.1 CERTIFICATE OF DESIGNATION OF SERIES B CONVERTIBLE PREFERRED STOCK OF HEDGEPATH PHARMACEUTICALS, INC. Pursuant to Section 151(g) of the Delaware General Corporation Law Pursuant to Section 151(g) of the General Corporation Law of the State of Delaware (the “DGCL”), the undersigned officer of HedgePath Pharmaceuticals, Inc., a corporation organized and e |
|
| January 11, 2018 |
8-K 1 d523601d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2018 (January 8, 2018) HedgePath Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-13467 30-079366 |
|
| January 11, 2018 |
Form of Warrant issued in the January 2018 Series B Preferred Stock Financing (9) EX-4.1 Exhibit 4.1 THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?ACT?), OR THE SECURITIES LAWS OF ANY STATE AND MAY NOT BE SOLD OR TRANSFERRED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT UNDER APPLICABLE FEDERAL AND STATE SECURITIES LAWS OR PURSUANT TO AN APPLICABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJEC |
|
| January 11, 2018 |
EX-99.1 Exhibit 99.1 HedgePath Pharmaceuticals Secures New Funding from Mayne Pharma to Support BCCNS Clinical and Regulatory Approval Programs HPPI receives three tranche preferred stock and warrant funding, with $2.4 million upfront, $1.6 million by mid-2018, and an additional $1 million by year end if BCCNS NDA is accepted HPPI?s Supply and License Agreement with Mayne Pharma amended to remove |
|
| January 11, 2018 |
EX-3.2 Exhibit 3.2 CERTIFICATE OF CORRECTION OF CERTIFICATE OF DESIGNATION, OF SERIES B CONVERTIBLE PREFERRED STOCK OF HEDGEPATH PHARMACEUTICALS, INC. HedgePath Pharmaceuticals, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the ?Corporation?), DOES HEREBY CERTIFY THAT: 1. The name of the corporation is HedgePath Pharmaceutic |
|
| January 11, 2018 |
EX-10.2 6 d523601dex102.htm EX-10.2 Exhibit 10.2 Confidential Treatment Requested by ITUS Corporation, IRS Employer Identification No. 30-0793665 ***CONFIDENTIAL TREATMENT REQUESTED*** NOTE: CONFIDENTIAL TREATMENT REQUESTED WITH RESPECT TO CERTAIN PORTIONS HEREOF DENOTED WITH “[***]” AMENDMENT NO. 2 TO SECOND AMENDED AND RESTATED SUPPLY AND LICENSE AGREEMENT AND AMENDMENT NO. 1 TO SUBLICENSE AGREE |
|
| January 11, 2018 |
Securities Purchase Agreement, dated January 8, 2018, between the Company and Mayne Pharma (9) EX-10.1 5 d523601dex101.htm EX-10.1 Exhibit 10.1 EXECUTION VERSION SECURITIES PURCHASE AGREEMENT Dated January 8, 2018 by and between HEDGEPATH PHARMACEUTICALS, INC. and MAYNE PHARMA VENTURES PTY LTD EXECUTION VERSION TABLE OF CONTENTS ARTICLE I SALE OF PURCHASED SECURITIES; CLOSING 6 1.1 Sale and Purchase of Purchased Securities 6 1.2 Closings 6 1.3 Use of Proceeds 7 ARTICLE II DEFINITIONS 7 2.1 |
|
| January 11, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 7)* HedgePath Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 42278K 102 (CUSIP Number) Kate Rintoul Mayne Pharma Ventures Pty Ltd 1538 Main North Road, Salisbury South 5106 SA, Australia 61 3 8614 7711 |
|
| January 11, 2018 |
Exhibit 99.1 JOINT FILING AGREEMENT Each of the undersigned hereby agrees that this Amendment No. 7 to Schedule 13D is being filed with the U.S. Securities and Exchange Commission on behalf of each of the undersigned pursuant to Rule 13d-1(k) under the U.S. Securities Exchange Act of 1934, as amended. Date: January 11, 2018 Mayne Pharma Ventures Pty Ltd /s/ Nick Freeman Nick Freeman, Company Secre |
|
| December 20, 2017 |
Submission of Matters to a Vote of Security Holders 8-K 1 d473651d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 20, 2017 (December 18, 2017) HedgePath Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-13467 30-079 |
|
| November 13, 2017 |
HPPI / HedgePath Pharmaceuticals, Inc. DEF 14A DEF 14A Table of Contents SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy Statement ? Definitive Additional Materials ? Soliciting Material Pursuant to ?240. |
|
| October 31, 2017 |
HedgePath Pharmaceuticals 10-Q (Quarterly Report) 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| October 5, 2017 |
EX-99.1 exploring new pathways to cancer therapy HedgePath Pharmaceuticals, Inc. 1 ? 2017 HedgePath Pharmaceuticals, Inc. All rights reserved Exhibit 99.1 Cautionary Note on Forward-Looking Statements; No Offer of Securities This presentation includes or incorporates by reference statements that constitute ?forward-looking statements? within the meaning of the U.S. federal securities laws. These s |
|
| October 5, 2017 |
Financial Statements and Exhibits, Other Events 8-K 1 d465248d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 5, 2017 (October 5, 2017) HedgePath Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-13467 30-07 |
|
| July 31, 2017 |
HedgePath Pharmaceuticals 10-Q (Quarterly Report) 10-Q 1 d313404d10q.htm 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2017 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to C |
|
| July 28, 2017 |
HPPI / HedgePath Pharmaceuticals, Inc. / Hedgepath, Llc - SC 13D/A Activist Investment SC 13D/A 1 d410505dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* HedgePath Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 42278K 102 (CUSIP Number) Nicholas J. Virca President 324 South Hyde Park Avenue, Suite 350 Tampa, FL |
|
| July 28, 2017 |
EX-99.1 Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, each of the undersigned does hereby consent and agree to the joint filing on behalf of each of them of this Schedule 13D, and to the inclusion of this Joint Filing Agreement as an exhibit thereto. Dated: March 17, 2016 HEDGEPATH, LLC By: /s/ James A. McNulty Name: Jam |
|
| July 27, 2017 |
Financial Statements and Exhibits, Other Events Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 27, 2017 (July 25, 2017) HedgePath Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-13467 30-0793665 (State or other jur |
|
| July 27, 2017 |
EX-99.1 Exhibit 99.1 HedgePath Pharmaceuticals Receives Clarity From FDA Regarding Pathway to Potential Regulatory Submission HPPI to proceed with streamlined 505(b)(2) regulatory pathway for SUBA?-Itraconazole as a treatment for Basal Cell Carcinoma Nevus Syndrome FDA provides written guidance on data from HPPI?s ongoing clinicial trial and the data requirements for NDA filing and potential FDA a |
|
| May 30, 2017 |
Financial Statements and Exhibits, Other Events 8-K 1 d514186d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 30, 2017 HedgePath Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-13467 30-0793665 (State or other |
|
| May 30, 2017 |
EX-99.1 2 d514186dex991.htm PRESS RELEASE Exhibit 99.1 HedgePath Pharmaceuticals Announces Granting of Type-C Meeting Request by FDA and Provides Positive Clinical Trial Update 35 subjects with Basal Cell Carcinoma Nevus Syndrome in ongoing Phase 2(b) trial have a median time on study of 32 weeks of dosing with SUBA™-Itraconazole Third interim analysis shows 97% of patients avoiding surgery with 3 |
|
| May 8, 2017 |
HedgePath Pharmaceuticals FORM 10-Q (Quarterly Report) 10-Q 1 d372685d10q.htm FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2017 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fro |
|
| April 21, 2017 |
As filed with the Securities and Exchange Commission on April 21, 2017 POS AM 1 d345769dposam.htm POST - EFFECTIVE AMENDMENT NO. 1 TO FORM S-1 Table of Contents As filed with the Securities and Exchange Commission on April 21, 2017 Registration No. 333-212092 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 HedgePath Pharmaceuticals, Inc. (Exact n |
|
| February 17, 2017 |
EX-10.11 3 d306040dex1011.htm 1ST AMENDMENT TO EMPLOYMENT AGREEMENT BETWEEN THE COMPANY AND GARRISON J. HASARA Exhibit 10.11 FIRST AMENDMENT TO EMPLOYMENT AGREEMENT THIS FIRST AMENDMENT TO EMPLOYMENT AGREEMENT (the “Amendment”), is dated and effective as of February 16, 2017 by and between HedgePath Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Garrison J. Hasara (the “Executi |
|
| February 17, 2017 |
Amendment No. 1 to Second Amended and Restated Supply and License Agrrement Exhibit 10.16 AMENDMENT NO. 1 TO SECOND AMENDED AND RESTATED SUPPLY AND LICENSE AGREEMENT THIS AMENDMENT NO. 1 TO SECOND AMENDED AND RESTATED SUPPLY AND LICENSE AGREEMENT (the “Amendment”), dated effective as of November 22, 2016 (the “Effective Date”), is by and among: (i) MAYNE PHARMA VENTURES PTY LTD, an Australian comp |
|
| February 17, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K Form 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 17, 2017 |
2nd Amendment to Employment Agreement between the Company and Nicholas J. Virca Exhibit 10.6 SECOND AMENDMENT TO EMPLOYMENT AGREEMENT THIS SECOND AMENDMENT TO EMPLOYMENT AGREEMENT (the “Amendment”), is dated and effective as of February 16, 2017 by and between HedgePath Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Nicholas J. Virca (the “Executive”). The Company and the Execu |
|
| January 24, 2017 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 24, 2017 HedgePath Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-13467 30-0793665 (State or other jurisdiction of |
|
| December 5, 2016 |
HedgePath Pharmaceuticals DEFINITIVE INFORMATION STATEMENT Definitive Information Statement SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| December 2, 2016 |
8-K 1 d306035d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 2, 2016 (November 30, 2016) HedgePath Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-13467 30 |
|
| December 2, 2016 |
Exhibit 99.1 JOINT FILING AGREEMENT Each of the undersigned hereby agrees that this Amendment No. 6 to Schedule 13D is being filed with the U.S. Securities and Exchange Commission on behalf of each of the undersigned pursuant to Rule 13d-1(k) under the U.S. Securities Exchange Act of 1934, as amended. Date: December 1, 2016 Mayne Pharma Ventures Pty Ltd /s/ Mark Cansdale Mark Cansdale, Company Sec |
|
| December 2, 2016 |
SC 13D/A 1 v454243sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 6)* HedgePath Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 42278K 102 (CUSIP Number) Kate Rintoul Mayne Pharma Ventures Pty Ltd Level 1, 99 King Street Melbourne |
|
| November 28, 2016 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 28, 2016 (November 22, 2016) HedgePath Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-13467 30-0793665 (State or o |
|
| November 28, 2016 |
Exhibit 99.1 JOINT FILING AGREEMENT Each of the undersigned hereby agrees that this Amendment No. 5 to Schedule 13D is being filed with the U.S. Securities and Exchange Commission on behalf of each of the undersigned pursuant to Rule 13d-1(k) under the U.S. Securities Exchange Act of 1934, as amended. Date: November 28, 2016 Mayne Pharma Ventures Pty Ltd /s/ Mark Cansdale Mark Cansdale, Company Se |
|
| November 28, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 5)* HedgePath Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 42278K 102 (CUSIP Number) Kate Rintoul Mayne Pharma Ventures Pty Ltd Level 1, 99 King Street Melbourne, Victoria 3000 Australia 61 3 8614 77 |
|
| November 16, 2016 |
SC 13D/A 1 v453180sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* HedgePath Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 42278K 102 (CUSIP Number) Kate Rintoul Mayne Pharma Ventures Pty Ltd Level 1, 99 King Street Melbourne |
|
| November 16, 2016 |
Exhibit 99.1 JOINT FILING AGREEMENT Each of the undersigned hereby agrees that this Amendment No. 4 to Schedule 13D is being filed with the U.S. Securities and Exchange Commission on behalf of each of the undersigned pursuant to Rule 13d-1(k) under the U.S. Securities Exchange Act of 1934, as amended. Date: November 15, 2016 Mayne Pharma Ventures Pty Ltd /s/ Mark Cansdale Mark Cansdale, Company Se |
|
| November 8, 2016 |
Changes in Control of Registrant Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2016 (November 2, 2016) HedgePath Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-13467 30-0793665 (State or oth |
|
| November 8, 2016 |
SC 13D/A 1 v452300sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* HedgePath Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 42278K 102 (CUSIP Number) Kate Rintoul Mayne Pharma Ventures Pty Ltd Level 1, 99 King Street Melbourne |
|
| November 8, 2016 |
EX-99.5 3 v452300ex99-5.htm EXHIBIT 99.5 Exhibit 99.5 |
|
| November 8, 2016 |
Exhibit 99.1 JOINT FILING AGREEMENT Each of the undersigned hereby agrees that this Amendment No. 3 to Schedule 13D is being filed with the U.S. Securities and Exchange Commission on behalf of each of the undersigned pursuant to Rule 13d-1(k) under the U.S. Securities Exchange Act of 1934, as amended. Date: November 7, 2016 Mayne Pharma Ventures Pty Ltd /s/ Mark Cansdale Mark Cansdale, Company Sec |
|
| October 31, 2016 |
HedgePath Pharmaceuticals FORM 10-Q (Quarterly Report) Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| October 24, 2016 |
HEDGEPATH PHARMACEUTICALS, INC. 2014 EQUITY INCENTIVE PLAN EX-99.1 4 d269036dex991.htm HEDGEPATH PHARMACEUTICALS, INC. 2014 EQUITY INCENTIVE PLAN Exhibit 99.1 HEDGEPATH PHARMACEUTICALS, INC. 2014 EQUITY INCENTIVE PLAN 1. Purpose. The purpose of the HedgePath Pharmaceuticals, Inc. 2014 Equity Incentive Plan is to provide a means through which the Company and its Affiliates may attract and retain key personnel and to provide a means whereby directors, offic |
|
| October 24, 2016 |
HedgePath Pharmaceuticals FORM S-8 Form S-8 Table of Contents As filed with the Securities and Exchange Commission on October 24, 2016 Registration No. |
|
| August 12, 2016 |
HedgePath Pharmaceuticals FROM 10-Q (Quarterly Report) From 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| July 26, 2016 |
85,296,000 Shares of Common Stock Final Prospectus Table of Contents Filed pursuant to Rule 424(b)(3) Registration No. |
|
| July 21, 2016 |
HedgePath Pharmaceuticals AMENDMENT NO. 2 TO FORM S-1 Amendment No. 2 to Form S-1 As filed with the Securities and Exchange Commission on July 20, 2016 Registration No. 333-212092 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 2 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 HedgePath Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 2834 30-0793665 (State |
|
| July 21, 2016 |
CORRESP 1 filename1.htm HedgePath Pharmaceuticals, Inc. 324 S. Hyde Park Avenue, Ste. 350 Tampa, Florida 33606 July 21, 2016 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attn: John Reynolds Re: HedgePath Pharmaceuticals, Inc. Registration Statement on Form S-1 File No. 333-212092 Dear Mr. Reynolds: Pursuant to Ru |
|
| July 18, 2016 |
HedgePath Pharmaceuticals AMENDMENT NO. 1 TO FORM S-1 S-1/A 1 d228665ds1a.htm AMENDMENT NO. 1 TO FORM S-1 Table of Contents As filed with the Securities and Exchange Commission on July 18, 2016 Registration No. 333-212092 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 HedgePath Pharmaceuticals, Inc. (Exact name of registrant as specified in it |
|
| July 18, 2016 |
SEC Response Letter 1345 AVENUE OF THE AMERICAS, 11th FLOOR NEW YORK, NEW YORK 10105 TELEPHONE: (212) 370-1300 FACSIMILE: (212) 370-7889 www. |
|
| June 17, 2016 |
As filed with the Securities and Exchange Commission on June 17, 2016 S-1 1 d210299ds1.htm FORM S-1 REGISTRATION STATEMENT Table of Contents As filed with the Securities and Exchange Commission on June 17, 2016 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 HedgePath Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 2834 |
|
| June 16, 2016 |
SC 13D/A 1 t1600395sc13da.htm SCHEDULE 13D (AMENDMENT NO. 2) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* HedgePath Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 42278K 102 (CUSIP Number) Kate Rintoul Level 1, 99 King Street Melbourne, Victo |
|
| June 1, 2016 |
Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2016 (May 25, 2016) HedgePath Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-13467 30-0793665 (State or other juris |
|
| May 26, 2016 |
Certificate of Amendment to the Company’s Certificate of Incorporation (5) Certificate of Amendment Exhibit 3.1 STATE OF DELAWARE CERTIFICATE OF AMENDMENT OF CERTIFICATE OF INCORPORATION OF HEDGEPATH PHARMACEUTICALS, INC. HedgePath Pharmaceuticals, Inc. (the Corporation), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the DGCL), does hereby certify: First: That the Board of Directors of the Corporatio |
|
| May 26, 2016 |
HedgePath Pharmaceuticals FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 26, 2016 (May 20, 2016) HedgePath Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-13467 30-0793665 (State or other juris |
|
| May 13, 2016 |
HedgePath Pharmaceuticals FORM 10-Q (Quarterly Report) Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 3, 2016 |
HedgePath Pharmaceuticals FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2016 (May 3, 2016) HedgePath Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-13467 30-0793665 (State or other juri |
|
| April 25, 2016 |
HedgePath Pharmaceuticals DEFINITIVE INFORMATION STATEMENT DEF 14C 1 d176923ddef14c.htm DEFINITIVE INFORMATION STATEMENT SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14C (RULE 14C-101) INFORMATION STATEMENT PURSUANT TO SECTION 14(C) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED Check the appropriate box: ¨ Preliminary Information Statement x Definitive Information Statement ¨ Confidential, for Use of the Commission Only (as perm |
|
| April 15, 2016 |
Form of Warrant issued in the 2016 Private Placement (8) Exhibit 4.1 THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ACT), OR THE SECURITIES LAWS OF ANY STATE AND MAY NOT BE SOLD OR TRANSFERRED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT UNDER APPLICABLE FEDERAL AND STATE SECURITIES LAWS OR PURSUANT TO AN APPLICABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, T |
|
| April 15, 2016 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 15, 2016 (April 11, 2016) HedgePath Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-13467 30-0793665 (State or other j |
|
| April 15, 2016 |
Form of Securities Purchase Agreement issued in the 2016 Private Placement (10) Form of Securities Purchase Agreement Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this ?Agreement?) is dated as of , 2016, between HedgePath Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), and each purchaser identified on the signature pages hereto, whether such purchaser is or becomes a signature as of the Initial Closing or any Subsequent Closing |
|
| April 12, 2016 |
HedgePath Pharmaceuticals PRELIMINARY INFORMATION STATEMENT PRE 14C 1 d176923dpre14c.htm PRELIMINARY INFORMATION STATEMENT SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14C (RULE 14C-101) INFORMATION STATEMENT PURSUANT TO SECTION 14(C) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED Check the appropriate box: x Preliminary Information Statement ¨ Definitive Information Statement ¨ Confidential, for Use of the Commission Only (as per |
|
| March 22, 2016 |
HedgePath Pharmaceuticals REQUEST FOR WITHDRAWAL RW 1 d68758drw.htm REQUEST FOR WITHDRAWAL HedgePath Pharmaceuticals, Inc. 324 S. Hyde Park Avenue, Ste. 350 Tampa, Florida 33606 March 22, 2016 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Mail Stop 3561 Washington, D.C. 20549 Attention: Ruairi J. Regan, Esq. Re: HedgePath Pharmaceuticals, Inc. Registration Statement on Form S-1 (File No. 333 |
|
| February 23, 2016 |
COMMON STOCK PURCHASE WARRANT HEDGEPATH PHARMACEUTICALS, INC. Warrant Shares: Issue Date: , 2016 EX-4.4 2 d68758dex44.htm FORM OF WARRANT Exhibit 4.4 COMMON STOCK PURCHASE WARRANT HEDGEPATH PHARMACEUTICALS, INC. Warrant Shares: Issue Date: , 2016 This COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or af |
|
| February 23, 2016 |
As filed with the Securities and Exchange Commission on February 23, 2016 S-1/A 1 d68758ds1a.htm AMENDMENT NO 1 TO FORM S-1 Table of Contents As filed with the Securities and Exchange Commission on February 23, 2016 Registration No. 333-208594 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 HedgePath Pharmaceuticals, Inc. (Exact name of registrant as specified in |
|
| February 23, 2016 |
Form of Subscription Agreement Exhibit 10.21 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of , 2016, between HedgePath Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto, whether such purchaser is or becomes a signature as of the Initial Closing or any Subsequent Closing (each |
|
| February 1, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K 10-K 1 d113219d10k.htm FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2015 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission |
|
| December 22, 2015 |
HedgePath Pharmaceuticals FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 22, 2015 (December 17, 2015) HedgePath Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-13467 30-0793665 (State or o |
|
| December 22, 2015 |
EX-10.1 2 d100976dex101.htm AMENDMENT NO. 1 TO AMENDED AND RESTATED EQUITY HOLDERS AGREEMENT Exhibit 10.1 AMENDMENT NO. 1 TO AMENDED AND RESTATED EQUITY HOLDERS’ AGREEMENT THIS AMENDMENT NO. 1 TO AMENDED AND RESTATED EQUITY HOLDERS’ AGREEMENT (the “Amendment”), dated effective as of December 17, 2015 (the “Effective Date”), is by and among: (i) MAYNE PHARMA VENTURES PTY LTD, an Australian company |
|
| December 17, 2015 |
HedgePath Pharmaceuticals FORM S-1 S-1 1 d68758ds1.htm FORM S-1 Table of Contents As filed with the Securities and Exchange Commission on December 17, 2015 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 HedgePath Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 2834 30-0793665 (State o |
|
| November 4, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q 10-Q 1 d18401d10q.htm 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2015 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file |
|
| September 9, 2015 |
HedgePath Pharmaceuticals FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 9, 2015 (September 2, 2015) HedgePath Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-13467 30-0793665 (State or o |
|
| September 9, 2015 |
EX-10.1 2 d85970dex101.htm SUBLICENSE AGREEMENT Confidential Treatment Requested by HedgePath Pharmaceuticals, Inc., IRS Employer Identification No. 30-0793665 Exhibit 10.1 ***CONFIDENTIAL TREATMENT REQUESTED*** Note: Confidential treatment requested with respect to certain portions hereof denoted with “***” September 2, 2015 SUBLICENSE AGREEMENT BETWEEN MAYNE PHARMA INTERNATIONAL PTY LTD & HEDGEP |
|
| August 14, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q 10-Q 1 d938337d10q.htm FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2015 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from |
|
| August 14, 2015 |
Exhibit 10.6 FOIA CONFIDENTIAL TREATMENT REQUEST BY HEDGEPATH PHARMACEUTICALS, INC. IRS EMPLOYER IDENTIFICATION NUMBER 30-0793665 ***CONFIDENTIAL TREATMENT REQUESTED*** Note: Confidential treatment requested with respect to certain portions hereof denoted with ?***? MASTER CLINICAL SERVICES AGREEMENT This Master Clinical Services Agreement (this ?Agreement?) is executed as of 15 June, 2015 and mad |
|
| August 14, 2015 |
EX-10.4 6 d938337dex104.htm SECOND AMENDED AND RESTATED SUPPLY AND LICENSE AGREEMENT Exhibit 10.4 FOIA CONFIDENTIAL TREATMENT REQUEST BY HEDGEPATH PHARMACEUTICALS, INC. IRS EMPLOYER IDENTIFICATION NUMBER 30-0793665 ***CONFIDENTIAL TREATMENT REQUESTED*** Note: Confidential treatment requested with respect to certain portions hereof denoted with “***” Final Date: May 15, 2015 Second Amended and Rest |
|
| August 14, 2015 |
EX-10.1 3 d938337dex101.htm AMENDED AND RESTATED EQUITY HOLDERS AGREEMENT Exhibit 10.1 EXECUTION VERSION HEDGEPATH PHARMACEUTICALS, INC. AMENDED AND RESTATED EQUITY HOLDERS’ AGREEMENT Dated As of May 15, 2015 HEDGEPATH PHARMACEUTICALS, INC. AMENDED AND RESTATED EQUITY HOLDERS’ AGREEMENT This AMENDED AND RESTATED EQUITY HOLDERS’ AGREEMENT (this “Agreement”) is made and entered into as of the 15th d |
|
| August 14, 2015 |
EX-10.3 5 d938337dex103.htm FIRST AMENDMENT TO EMPLOYMENT AGREEMENT Exhibit 10.3 EXECUTION VERSION FIRST AMENDMENT TO EMPLOYMENT AGREEMENT THIS FIRST AMENDMENT TO EMPLOYMENT AGREEMENT (the “Amendment”), is dated as of May 15, 2015 by and between HedgePath Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Nicholas J. Virca (the “Executive”). The Company and the Executive are referr |
|
| August 14, 2015 |
HEDGEPATH PHARMACEUTICALS, INC. Common Stock Purchase Warrant EX-4.1 2 d938337dex41.htm WARRANT Exhibit 4.1 EXECUTION VERSION THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND MAY NOT BE SOLD OR TRANSFERRED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT UNDER APPLICABLE FEDERAL AND STATE SECURITIES LAWS OR PURSUANT TO AN APPLICABLE E |
|
| August 14, 2015 |
FIRST AMENDMENT TO EXECUTIVE CHAIRMAN AGREEMENT Exhibit 10.2 EXECUTION VERSION FIRST AMENDMENT TO EXECUTIVE CHAIRMAN AGREEMENT THIS FIRST AMENDMENT TO EXECUTIVE CHAIRMAN AGREEMENT (the ?Amendment?), is dated as of May 15, 2015, by and between HedgePath Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), and Frank E. O?Donnell, Jr., M.D. (the ?Executive Chairman?). The Company and the Executive Chairman are referred to collectively he |
|
| August 14, 2015 |
EX-10.5 7 d938337dex105.htm SECURITIES PURCHASE AGREEMENT Exhibit 10.5 EXECUTION VERSION SECURITIES PURCHASE AGREEMENT Dated May 15, 2015 by and between HEDGEPATH PHARMACEUTICALS, INC. and MAYNE PHARMA VENTURES PTY LTD TABLE OF CONTENTS Page ARTICLE I SALE AND PURCHASE OF PURCHASED SECURITIES; CLOSING 2 1.1 Sale and Purchase of Purchased Securities 2 1.2 Closing 2 ARTICLE II DEFINITIONS 3 2.1 Defi |
|
| August 10, 2015 |
30,600,000 Shares Common Stock 424B3 1 d783002d424b3.htm 424B(3) Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-198800 Prospectus 30,600,000 Shares Common Stock This prospectus relates to the offer for sale of up to a potential aggregate of 30,600,000 shares of common stock, par value $0.0001 per share, of HedgePath Pharmaceuticals, Inc. by the selling stockholders named herein. We are not offering any |
|
| August 6, 2015 |
CORRESP 1 filename1.htm HedgePath Pharmaceuticals, Inc. 324 S. Hyde Park Avenue, Ste. 350 Tampa, Florida 33606 August 6, 2015 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attn: Jeffrey P. Riedler Re: HedgePath Pharmaceuticals, Inc. Registration Statement on Form S-1 File No. 333-198800 Dear Mr. Riedler: Pursuant |
|
| July 22, 2015 |
As filed with the Securities and Exchange Commission on July 22, 2015 S-1/A 1 d783002ds1a.htm AMENDMENT NO 1 TO FORM S-1 Table of Contents As filed with the Securities and Exchange Commission on July 22, 2015 Registration No. 333-198800 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 HedgePath Pharmaceuticals, Inc. (Exact name of registrant as specified in its |
|
| July 22, 2015 |
Certificate of Amendment to the Company’s Certificate of Incorporation (3) Certificate of Amendment EXHIBIT 3.3 STATE OF DELAWARE CERTIFICATE OF AMENDMENT OF CERTIFICATE OF INCORPORATION OF HEDGEPATH PHARMACEUTICALS, INC. HedgePath Pharmaceuticals, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify: First: That the Board of Directors of the Corporatio |
|
| June 16, 2015 |
HedgePath Pharmaceuticals DEFINITIVE INFORMATION STATEMENT Definitive Information Statement SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| June 3, 2015 |
HedgePath Pharmaceuticals PRELIMINARY INFORMATION STATEMENT PRE 14C 1 d935591dpre14c.htm PRELIMINARY INFORMATION STATEMENT SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14C (RULE 14C-101) INFORMATION STATEMENT PURSUANT TO SECTION 14(C) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: x Preliminary Information Statement ¨ |
|
| May 22, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* HedgePath Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 42278K 102 (CUSIP Number) Kate Rintoul Level 14, 474 Flinders Street Melbourne, Victoria 3000 Australia 61 3 8614 7711 (Name, Address and Te |
|
| May 21, 2015 |
Second Amended and Restated Bylaws of the Company (4) Second Amended and Restated ByLaws Exhibit 3.1 SECOND AMENDED AND RESTATED BYLAWS OF HEDGEPATH PHARMACEUTICALS, INC. (a Delaware Corporation) (adopted effective as of May 15, 2015) ARTICLE 1 OFFICES SECTION 1.1. Principal Office. The principal offices of the HedgePath Pharmaceuticals, Inc., a Delaware corporation (the ?Corporation?) shall be in such location as the Board of Directors of the Corpor |
|
| May 21, 2015 |
8-K 1 d932170d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2015 (May 15, 2015) HedgePath Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-13467 30-0793665 |
|
| May 13, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2015 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-1 |
|
| February 13, 2015 |
Exhibit 14 HEDGEPATH PHARMACEUTICALS, INC. CODE OF ETHICAL CONDUCT Preface The honesty, integrity, ethics, respect for others and sound judgment displayed by directors, principal executives and financial officers of HedgePath Pharmaceuticals, Inc. (?HPPI?) set the tone for business conduct, and are fundamental to the proper functioning, reputation and success of HPPI. This Code of Ethical Conduct |
|
| February 13, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K 10-K 1 d831773d10k.htm 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2014 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file |
|
| October 14, 2014 |
DEF 14C 1 d798287ddef14c.htm DEFINITIVE INFORMATION STATEMENT SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 INFORMATION STATEMENT PURSUANT TO SECTION 14(C) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED SCHEDULE 14C (RULE 14C-101) Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ¨ Preliminary Information Statement ¨ C |
|
| October 10, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q 10-Q 1 d772477d10q.htm FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2014 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period |
|
| October 3, 2014 |
INTI / Inhibitor Therapeutics, Inc. PRE 14C - - PRELIMINARY INFORMATION STATEMENT Preliminary Information Statement SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| September 17, 2014 |
INTI / Inhibitor Therapeutics, Inc. S-1 - Registration Statement - FORM S-1 S-1 1 d783002ds1.htm FORM S-1 Table of Contents As filed with the Securities and Exchange Commission on September 17, 2014 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 HedgePath Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 2834 30-0793665 (State |
|
| September 9, 2014 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 9, 2014 (September 4, 2014) HedgePath Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-13467 30-0793665 (State or o |
|
| September 9, 2014 |
Employment Agreement, dated September 4, 2014, between the Company and Garrison J. Hasara (4) Employment Agreement, dated September 4, 2014, with Garrison J. Hasara Exhibit 10.1 FOIA CONFIDENTIAL TREATMENT REQUEST BY HEDGEPATH PHARMACEUTICALS, INC. IRS EMPLOYER IDENTIFICATION NUMBER 30-0793665 Confidential treatment requested with respect to certain portions hereof denoted with “***” ***CONFIDENTIAL TREATMENT REQUESTED*** Note: Confidential treatment requested with respect to certain porti |
|
| August 13, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2014 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-13 |
|
| July 24, 2014 |
EX-3.1 2 d762792dex31.htm AMENDED AND RESTATED BYLAWS OF THE COMPANY Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF HEDGEPATH PHARMACEUTICALS, INC. (a Delaware Corporation) (adopted effective as of July 18, 2014) ARTICLE 1 OFFICES SECTION 1.1. Principal Office. The principal offices of the HedgePath Pharmaceuticals, Inc., a Delaware corporation (the “Corporation”) shall be in such location as the Boar |
|
| July 24, 2014 |
8-K 1 d762792d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2014 (July 18, 2014) HedgePath Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-13467 30-079366 |
|
| July 11, 2014 |
Schedule 13D Amendment No. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* HedgePath Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 42278K 102 (CUSIP Number) Nicholas J. Virca President 324 South Hyde Park Avenue, Suite 350 Tampa, FL 33606 (81 |
|
| July 7, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* HedgePath Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 42278K 102 (CUSIP Number) Kate Rintoul Level 14, 474 Flinders Street Melbourne, Victoria 3000 Australia 61 3 8614 7711 (Name, Address and Telep |
|
| July 7, 2014 |
Exhibit 99.1 JOINT FILING AGREEMENT The undersigned, being duly authorized thereunto, hereby execute this agreement as an exhibit to this Schedule 13D to evidence the agreement of the below-named parties, in accordance with the rules promulgated pursuant to the Securities Exchange Act of 1934, to file this Schedule 13D jointly on behalf of each such party. Date: July 7, 2014 MAYNE PHARMA VENTURES |
|
| June 30, 2014 |
PROMISSORY NOTE US$1,250,000.00 Dated as of June 24, 2014 EX-10.3 6 d750157dex103.htm PROMISSORY NOTE Exhibit 10.3 PROMISSORY NOTE US$1,250,000.00 Dated as of June 24, 2014 This PROMISSORY NOTE (this “Note”) is being issued and delivered pursuant to the terms of that certain Stock Purchase Agreement, dated June 24, 2014 (the “Purchase Agreement”), by and between the Maker (as defined below) and the Payee (as defined below). All capitalized terms used but |
|
| June 30, 2014 |
Amended and Restated Supply and License Agreement Confidential Treatment Requested by HedgePath Pharmaceuticals, Inc. |
|
| June 30, 2014 |
Debt Forgiveness Agreement Exhibit 10.5 DEBT FORGIVENESS AGREEMENT THIS DEBT FORGIVENESS AGREEMENT (this “Agreement”) is made and entered into and effective as of this 24th day of June, 2014 by and between HEDGEPATH PHARMACEUTICALS, INC., a Delaware corporation (“HPPI”), and HEDGEPATH, LLC a Delaware limited liability company (“HP LLC”). WHEREAS, on the terms and subject to the conditions set fort |
|
| June 30, 2014 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2014 (June 24, 2014) HedgePath Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-13467 30-0793665 (State or other jurisdic |
|
| June 30, 2014 |
Employment Agreement, dated June 24, 2014, between the Company and Nicholas J. Virca (3)+ EX-10.6 9 d750157dex106.htm EMPLOYMENT AGREEMENT Confidential Treatment Requested by HedgePath Pharmaceuticals, Inc., IRS Employer Identification No. 30-0793665 Confidential treatment requested with respect to certain portions hereof denoted with “***” Exhibit 10.6 ***CONFIDENTIAL TREATMENT REQUESTED*** Note: Confidential treatment requested with respect to certain portions hereof denoted with “** |
|
| June 30, 2014 |
Executive Chairman Agreement Exhibit 10.7 EXECUTIVE CHAIRMAN AGREEMENT THIS EXECUTIVE CHAIRMAN AGREEMENT (the “Agreement”) is made as of the 24th day of June, 2014 (the “Effective Date”) and is by and between HedgePath Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Frank E. O’Donnell. Jr., M.D. (the “Executive Chairman”). WHEREAS, the Executive Chairman is presently serving in |
|
| June 30, 2014 |
Warrant, dated June 24, 2014 issued to Hedgepath, LLC, as filed with Form 8-K, dated June 30, 2014 EX-4.1 2 d750157dex41.htm WARRANT Exhibit 4.1 THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND MAY NOT BE SOLD OR TRANSFERRED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT UNDER APPLICABLE FEDERAL AND STATE SECURITIES LAWS OR PURSUANT TO AN APPLICABLE EXEMPTION FROM, OR |
|
| June 30, 2014 |
EX-10.2 5 d750157dex102.htm STOCK PURCHASE AGREEMENT Exhibit 10.2 STOCK PURCHASE AGREEMENT This STOCK PURCHASE AGREEMENT (this “Agreement”), dated as of June 24, 2014, is made and entered into by and between HedgePath Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Hedgepath, LLC, a Florida limited liability company (the “Purchaser”). WHEREAS, the Company desires to raise capita |
|
| June 30, 2014 |
Warrant, dated June 24, 2014 issued to Hedgepath, LLC (7) EX-4.2 3 d750157dex42.htm WARRANT Exhibit 4.2 THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND MAY NOT BE SOLD OR TRANSFERRED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT UNDER APPLICABLE FEDERAL AND STATE SECURITIES LAWS OR PURSUANT TO AN APPLICABLE EXEMPTION FROM, OR |
|
| June 30, 2014 |
Equity Holders Agreement Exhibit 10.4 Confidential Treatment Requested by HedgePath Pharmaceuticals, Inc., IRS Employer Identification No. 30-0793665 Confidential treatment requested with respect to certain portions hereof denoted with “***” Exhibit 10.4 ***CONFIDENTIAL TREATMENT REQUESTED*** Note: Confidential treatment requested with respect to certain portions hereof denoted with “***” HEDGEPAT |
|
| June 30, 2014 |
EX-10.1 4 d750157dex101.htm SECURITIES PURCHASE AGREEMENT Exhibit 10.1 SECURITIES PURCHASE AGREEMENT Dated June 24, 2014 by and between HEDGEPATH PHARMACEUTICALS, INC. and MAYNE PHARMA VENTURES PTY LTD TABLE OF CONTENTS Page ARTICLE I SALE OF PURCHASED SECURITIES; CLOSING 2 1.1 Purchase 2 1.2 Closing 2 ARTICLE II DEFINITIONS 2 2.1 Definitions 2 ARTICLE III REPRESENTATIONS AND WARRANTIES 7 3.1 Repr |
|
| May 12, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2014 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-1 |
|
| April 15, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2013 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-13467 HedgePath P |
|
| March 31, 2014 |
NT 10-K 1 d650079dnt10k.htm NOTIFICATION OF LATE FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC File Number: 001-13467 (Check One): x Form 10-K ¨ Form 20-F ¨ Form 11-K ¨ Form 10-Q ¨ Form N-SAR ¨ Form N-CSR For Period Ended: December 31, 2013 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Repor |
|
| March 11, 2014 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits - FORM 8-K FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2014 (March 5, 2014) HedgePath Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-13467 30-0793665 (State or other ju |
|
| March 11, 2014 |
[Signature Page to Amendment No. 2 to Supply and License Agreement] Amendment No. 2 to Supply and License Agreement Exhibit 10.1 March 6, 2014 Mr. Nick Virca President and CEO, HedgePath Pharmaceuticals, Inc. [email protected] Dear Nick: Amendment No. 2 to Supply and License Agreement We refer to the supply and license agreement dated, September 3, 2013, between Mayne Pharma International Pty Ltd and HedgePath Pharmaceuticals, Inc., as amended (Agreement) |
|
| December 23, 2013 |
[Signature Page to Amendment No. 1 to Supply and License Agreement] Amendment No. 1 to Supply and License Agreement Exhibit 10.1 Mr. Nick Virca President and CEO, HedgePath Pharmaceuticals, Inc. [email protected] Dear Nick: Amendment No. 1 to Supply and License Agreement We refer to the supply and license agreement dated, September 3, 2013, between Mayne Pharma International Pty Ltd and HedgePath Pharmaceuticals, Inc. (Agreement). For due and valuable con |
|
| December 23, 2013 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 23, 2013 (December 17, 2013) HedgePath Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-13467 30-0793665 (State or o |
|
| November 14, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2013 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0 |
|
| September 10, 2013 |
8-K 1 d595990d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 10, 2013 (September 3, 2013) HedgePath Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-13467 |
|
| September 10, 2013 |
Amended and Restated Certificate of Designation for Series A Preferred Stock (2) Amended and Restated Certificate of Designation Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF DESIGNATION OF SERIES A CONVERTIBLE PREFERRED STOCK OF HEDGEPATH PHARMACEUTICALS, INC. Pursuant to Section 151(g) of the Delaware General Corporation Law Pursuant to Section 151(g) of the General Corporation Law of the State of Delaware (the “DGCL”), the undersigned officer of HedgePath Pharmaceuticals, |
|
| September 10, 2013 |
Supply and License Agreement Exhibit 10.1 Confidential Treatment Requested by HedgePath Pharmaceuticals, Inc., IRS Employer Identification No. 30-0793665 Confidential treatment requested with respect to certain portions hereof denoted with “***” ***CONFIDENTIAL TREATMENT REQUESTED*** Final Date: 3 September 2013 Supply and License Agreement Mayne Pharma International Pty Ltd (Mayne Pharma) HedgePa |
|
| September 10, 2013 |
Press Release Exhibit 99.1 HedgePath Pharmaceuticals Enters into Key Collaboration with Mayne Pharma Acquires Exclusive U.S. Rights for use of Mayne Pharma’s SUBA™ Itraconazole for treatment of cancer Mayne Pharma to supply product to HPPI, and companies to jointly pursue clinical development of SUBA Itraconazole for multiple oncology indications TAMPA, FLORIDA and SAN DIEGO, CALIFORNIA – (Septemb |
|
| September 6, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q 10-Q 1 d594010d10q.htm FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2013 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from |
|
| August 28, 2013 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant 8-K 1 d593554d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 28, 2013 (August 13, 2013) HedgePath Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-13467 30-07 |
|
| August 28, 2013 |
PBMares, LLP Letter Exhibit 16.1 August 28, 2013 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Ladies and Gentlemen: We have read Item 4.01 of Form 8-K dated August 28, 2013 of HedgePath Pharmaceuticals, Inc. (successor to Commonwealth Biotechnologies, Inc.) and are in agreement with the statements contained within Item 4.01 therein. We have no basis to agree or disagr |
|
| August 23, 2013 |
INTI / Inhibitor Therapeutics, Inc. / ODONNELL FRANCIS E JR - SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* HedgePath Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 42278K 102 (CUSIP Number) Nicholas J. Virca President 324 South Hyde Park Avenue, Suite 350 Tampa, FL 33606 (813) 864-2559 (Name, Address and T |
|
| August 23, 2013 |
EX-99.1 2 d588665dex991.htm JOINT FILING AGREEMENT Exhibit 99.1 JOINT FILING AGREEMENT The undersigned, being duly authorized thereunto, hereby execute this agreement as an exhibit to this Schedule 13D to evidence the agreement of the below-named parties, in accordance with the rules promulgated pursuant to the Securities Exchange Act of 1934, to file this Schedule 13D jointly on behalf of each su |
|
| August 16, 2013 |
STATE OF DELAWARE CERTIFICATE OF OWNERSHIP AND MERGER Certificate of Ownership and Merger Exhibit 3.4 STATE OF DELAWARE CERTIFICATE OF OWNERSHIP AND MERGER Section 253 Parent into Subsidiary CERTIFICATE OF OWNERSHIP AND MERGER MERGING Commonwealth Biotechnologies Inc., a Virginia corporation WITH AND INTO HedgePath Pharmaceuticals, Inc., a Delaware corporation Commonwealth Biotechnologies, Inc. (“Parent” or the “Corporation”), a corporation organized |
|
| August 16, 2013 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 16, 2013 (August 12, 2013) HedgePath Pharmaceuticals, Inc. |
|
| August 16, 2013 |
AGREEMENT AND PLAN OF MERGER AND REORGANIZATION EX-2.1 2 d584597dex21.htm AGREEMENT AND PLAN OF MERGER AND REORGANIZATION Exhibit 2.1 AGREEMENT AND PLAN OF MERGER AND REORGANIZATION This AGREEMENT AND PLAN OF MERGER AND REORGANIZATION, dated as of August 9, 2013 (the “Agreement”), by and between Commonwealth Biotechnologies, Inc., a Virginia corporation (the “Corporation”), and HedgePath Pharmaceuticals, Inc., a Delaware corporation and a wholl |
|
| August 16, 2013 |
EX-3.2 4 d584597dex32.htm BYLAWS Exhibit 3.2 BYLAWS OF HEDGEPATH PHARMACEUTICALS, INC. (a Delaware Corporation) (adopted effective as of July 30, 2013) ARTICLE 1 OFFICES SECTION 1.1. Principal Office. The principal offices of the HedgePath Pharmaceuticals, Inc., a Delaware corporation (the “Corporation”) shall be in such location as the Board of Directors of the Corporation (the “Board of Director |
|
| August 16, 2013 |
EX-10.1 7 d584597dex101.htm CONTRIBUTION AGREEMENT Exhibit 10.1 CONTRIBUTION AGREEMENT This CONTRIBUTION AGREEMENT (the “Agreement”) is entered into as of August 13, 2013 (the “Effective Date”), by and between Hedgepath, LLC, a Florida limited liability company (formerly known as Hedgepath Pharmaceuticals, Inc., a Florida corporation, “Hedgepath”), and HedgePath Pharmaceuticals, Inc., a Delaware c |
|
| August 16, 2013 |
Certificate of Incorporation of the Company (1) EX-3.1 3 d584597dex31.htm ARTICLES OF INCORPORATION Exhibit 3.1 CERTIFICATE OF INCORPORATION OF HEDGEPATH PHARMACEUTICALS, INC. The undersigned, for the purposes of forming a corporation under the laws of the State of Delaware, does make, file and record this Certificate of Incorporation, and does hereby certify as follows: FIRST: The name of the corporation is HedgePath Pharmaceuticals, Inc. (the |
|
| August 16, 2013 |
Certificate of Designation Exhibit 3.3 CERTIFICATE OF DESIGNATION OF SERIES A CONVERTIBLE PREFERRED STOCK OF HEDGEPATH PHARMACEUTICALS, INC. Pursuant to Section 151 of the Delaware General Corporation Law HedgePath Pharmaceuticals, Inc., a Delaware corporation (the “Corporation”), in accordance with the provisions of Section 103 of the Delaware General Corporation Law (the “DGCL”) does hereby cert |
|
| May 20, 2013 |
FORM 10-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 10-K 1 d512804d10k.htm FORM 10-K Table of Contents FORM 10-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 x ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2012 ¨ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-13467 COM |
|
| May 20, 2013 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2013 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-13467 COMMONWEALTH BIO |
|
| May 15, 2013 |
Notification of Late Filing SEC FILE NUMBER 001-13467 CUSIP NUMBER 202789 10 8 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
